Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farxiga vs Daonil in CAD and T2DM
NCT02919345Phase 4Completed
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD), sponsored by Universidade Estadual de Campinas. Primary endpoint: Flow Mediated Dilation at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02919345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919345.